

Maria Jose Morilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8955732/publications.pdf>

Version: 2024-02-01

55
papers

1,585
citations

236612

25
h-index

315357

38
g-index

55
all docs

55
docs citations

55
times ranked

2197
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Enhancing the anti-psoriatic activity of vitamin D3 employing nanostructured archaeolipid carriers. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 73, 103455. | 1.4 | 2 |
| 2 | Macrophage apoptosis using alendronate in targeted nanoarchaeosomes. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 160, 42-54. | 2.0 | 12 |
| 3 | Preclinical autophagy modulatory nanomedicines: big challenges, slow advances. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1415-1434. | 2.4 | 1 |
| 4 | Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. <i>Pharmaceutics</i> , 2021, 13, . | 2.0 | 1 |
| 5 | Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. <i>Pharmaceutics</i> , 2021, 13, 1331. | 2.0 | 7 |
| 6 | Fast Biofilm Penetration and Anti-PAO1 Activity of Nebulized Azithromycin in Nanoarchaeosomes. <i>Molecular Pharmaceutics</i> , 2020, 17, 70-83. | 2.3 | 14 |
| 7 | Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-targeted nanoparticles as potential intestinal repairing agent. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 191, 110961. | 2.5 | 21 |
| 8 | Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 179, 479-487. | 2.5 | 24 |
| 9 | The anti MRSA biofilm activity of <i>Thymus vulgaris</i> essential oil in nanovesicles. <i>Phytomedicine</i> , 2019, 57, 339-351. | 2.3 | 34 |
| 10 | Novel imiquimod nanovesicles for topical vaccination. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 174, 536-543. | 2.5 | 8 |
| 11 | G5G2.5 core-shell tecto-dendrimer specifically targets reactive glia in brain ischemia. <i>Journal of Neurochemistry</i> , 2018, 144, 748-760. | 2.1 | 12 |
| 12 | Nanotoxicity of Lipid-Based Nanomedicines. , 2018, , 133-165. | | 1 |
| 13 | Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 163. | 2.0 | 15 |
| 14 | Topical vaccination with super-stable ready to use nanovesicles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 152, 114-123. | 2.5 | 19 |
| 15 | Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. <i>Nanomedicine</i> , 2017, 12, 1165-1175. | 1.7 | 26 |
| 16 | Nebulizing novel multifunctional nanovesicles: the impact of macrophage-targeted-pH-sensitive archaeosomes on a pulmonary surfactant. <i>Journal of Materials Chemistry B</i> , 2017, 5, 8083-8095. | 2.9 | 18 |
| 17 | Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes. <i>Nanomedicine</i> , 2016, 11, 2103-2117. | 1.7 | 30 |
| 18 | Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 139, 190-198. | 2.5 | 118 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Ultradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis Antigens. PLoS ONE, 2016, 11, e0150185. | 1.1 | 25 |
| 20 | Carrier Deformability in Drug Delivery. Current Pharmaceutical Design, 2016, 22, 1118-1134. | 0.9 | 19 |
| 21 | Nanomedical Therapeutic and Prophylaxis Strategies Against Intracellular Protozoa in the Americas. , 2015, , 297-317. | | 2 |
| 22 | Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine, 2015, 10, 465-481. | 1.7 | 52 |
| 23 | Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes. International Journal of Nanomedicine, 2014, 9, 3335. | 3.3 | 19 |
| 24 | Physicochemical characterization and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery systems. Colloids and Surfaces B: Biointerfaces, 2014, 117, 1-6. | 2.5 | 29 |
| 25 | Enhanced antimelanoma activity of methotrexate and zoledronic acid within polymeric sandwiches. Colloids and Surfaces B: Biointerfaces, 2014, 122, 19-29. | 2.5 | 11 |
| 26 | Structural features of ultradeformable archaeosomes for topical delivery of ovalbumin. Colloids and Surfaces B: Biointerfaces, 2014, 121, 281-289. | 2.5 | 25 |
| 27 | Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease. Human Vaccines and Immunotherapeutics, 2013, 9, 409-412. | 1.4 | 18 |
| 28 | Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. International Journal of Nanomedicine, 2013, 8, 3171. | 3.3 | 89 |
| 29 | The Intervention of Nanotechnology Against Epithelial Fungal Diseases. Journal of Biomaterials and Tissue Engineering, 2013, 3, 70-88. | 0.0 | 12 |
| 30 | Increased brain radioactivity by intranasal ³² P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. International Journal of Nanomedicine, 2012, 7, 1373. | 3.3 | 40 |
| 31 | Ultradeformable archaeosomes as new topical adjuvants. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1319-1328. | 1.7 | 51 |
| 32 | In vitro phototoxicity of ultradeformable liposomes containing chloroaluminum phthalocyanine against New World Leishmania species. Journal of Photochemistry and Photobiology B: Biology, 2012, 117, 157-163. | 1.7 | 46 |
| 33 | Selective cytotoxicity of PAMAM G5 core–PAMAM G2.5 shell tecto-dendrimers on melanoma cells. International Journal of Nanomedicine, 2012, 7, 4121. | 3.3 | 31 |
| 34 | Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. International Journal of Nanomedicine, 2011, 6, 2715. | 3.3 | 30 |
| 35 | Topical and mucosal liposomes for vaccine delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 356-375. | 3.3 | 38 |
| 36 | M Cells Prefer Archaeosomes: An In Vitro/In Vivo Snapshot Upon Oral Gavage in Rats. Current Drug Delivery, 2011, 8, 320-329. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Intracellular Bacteria and Protozoa. <i>Fundamental Biomedical Technologies</i> , 2011, , 745-811. | 0.2 | 0 |
| 38 | Nanotechnological approaches against Chagas disease. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 576-588. | 6.6 | 64 |
| 39 | Sunlight triggered photodynamic ultradeformable liposomes against <i>Leishmania braziliensis</i> are also leishmanicidal in the dark. <i>Journal of Controlled Release</i> , 2010, 147, 368-376. | 4.8 | 61 |
| 40 | Archaeosomes made of Halorubrum tebenquichensetotal polar lipids: a new source of adjuvancy. <i>BMC Biotechnology</i> , 2009, 9, 71. | 1.7 | 36 |
| 41 | Avoiding failed reconstitution of ultradeformable liposomes upon dehydration. <i>International Journal of Pharmaceutics</i> , 2009, 372, 184-190. | 2.6 | 22 |
| 42 | Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. <i>International Journal of Pharmaceutics</i> , 2009, 380, 189-200. | 2.6 | 57 |
| 43 | Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. <i>International Journal of Pharmaceutics</i> , 2008, 360, 204-212. | 2.6 | 21 |
| 44 | Drug delivery systems against leishmaniasis? Still an open question. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 805-823. | 2.4 | 60 |
| 45 | Photodynamic ultradeformable liposomes: Design and characterization. <i>International Journal of Pharmaceutics</i> , 2007, 330, 183-194. | 2.6 | 31 |
| 46 | Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. <i>International Journal of Pharmaceutics</i> , 2006, 326, 160-168. | 2.6 | 53 |
| 47 | Etanidazole in pH-sensitive liposomes: Design, characterization and in vitro/in vivo anti- <i>Trypanosoma cruzi</i> activity. <i>Journal of Controlled Release</i> , 2005, 103, 599-607. | 4.8 | 46 |
| 48 | Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2005, 100, 213-219. | 0.8 | 19 |
| 49 | In vitro activity of Etanidazole against the protozoan parasite <i>Trypanosoma cruzi</i> . <i>Memorias Do Instituto Oswaldo Cruz</i> , 2004, 99, 233-235. | 0.8 | 15 |
| 50 | Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. <i>International Journal of Pharmaceutics</i> , 2004, 278, 311-318. | 2.6 | 50 |
| 51 | Liposomal Benznidazole: A High-Performance Liquid Chromatographic Determination for Biodistribution Studies. <i>Journal of Chromatographic Science</i> , 2003, 41, 405-409. | 0.7 | 13 |
| 52 | Development and in vitro characterisation of a benznidazole liposomal formulation. <i>International Journal of Pharmaceutics</i> , 2002, 249, 89-99. | 2.6 | 42 |
| 53 | On the mechanism of hepatic transendothelial passage of large liposomes. <i>FEBS Letters</i> , 1999, 448, 193-196. | 1.3 | 70 |
| 54 | Ultradeformable phospholipid vesicles as a drug delivery system: a review. <i>Research and Reports in Transdermal Drug Delivery</i> , 0, , 55. | 0.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Toll like receptors agonists-based nanomedicines as veterinary immunotherapies. Precision Nanomedicine, 0, , . | 0.4 | 1 |